Marshall Wace North America L.P. trimmed its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 44.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 156,739 shares of the biotechnology company’s stock after selling 123,102 shares during the period. Marshall Wace North America L.P.’s holdings in Sarepta Therapeutics were worth $25,315,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 5,384,899 shares of the biotechnology company’s stock worth $869,715,000 after purchasing an additional 170,999 shares during the period. Legal & General Group Plc increased its stake in Sarepta Therapeutics by 3.8% in the 3rd quarter. Legal & General Group Plc now owns 29,239 shares of the biotechnology company’s stock worth $4,723,000 after purchasing an additional 1,074 shares during the period. TIAA CREF Investment Management LLC increased its stake in Sarepta Therapeutics by 35.5% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 281,890 shares of the biotechnology company’s stock worth $45,528,000 after purchasing an additional 73,792 shares during the period. Teachers Advisors LLC increased its stake in Sarepta Therapeutics by 41.6% in the 3rd quarter. Teachers Advisors LLC now owns 132,916 shares of the biotechnology company’s stock worth $21,467,000 after purchasing an additional 39,036 shares during the period. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in Sarepta Therapeutics in the 3rd quarter worth approximately $3,715,000. 90.85% of the stock is currently owned by institutional investors.

Shares of SRPT stock opened at $121.38 on Friday. Sarepta Therapeutics Inc has a fifty-two week low of $50.68 and a fifty-two week high of $176.50. The company has a quick ratio of 7.84, a current ratio of 8.85 and a debt-to-equity ratio of 0.65.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.29). Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. The firm had revenue of $78.49 million for the quarter, compared to the consensus estimate of $78.84 million. As a group, research analysts anticipate that Sarepta Therapeutics Inc will post -4.38 earnings per share for the current year.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $140.50, for a total transaction of $936,713.50. Following the sale, the director now directly owns 126,534 shares in the company, valued at $17,778,027. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Sandesh Mahatme sold 107,524 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, October 24th. The shares were sold at an average price of $127.74, for a total value of $13,735,115.76. Following the sale, the chief financial officer now owns 48,381 shares in the company, valued at $6,180,188.94. The disclosure for this sale can be found here. Insiders own 7.90% of the company’s stock.

A number of equities analysts have commented on SRPT shares. Cantor Fitzgerald started coverage on Sarepta Therapeutics in a research note on Monday, October 1st. They issued an “overweight” rating and a $217.00 price target on the stock. Credit Suisse Group started coverage on Sarepta Therapeutics in a research note on Thursday, September 6th. They issued an “outperform” rating and a $178.00 price target on the stock. Bank of America started coverage on Sarepta Therapeutics in a research note on Friday, September 14th. They issued a “buy” rating and a $199.00 price target on the stock. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, August 24th. Finally, HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-three have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $169.19.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2018/12/08/marshall-wace-north-america-l-p-decreases-position-in-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Featured Story: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.